vs
Side-by-side financial comparison of Taysha Gene Therapies, Inc. (TSHA) and VirTra, Inc (VTSI). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $2.9M, roughly 1.9× VirTra, Inc). VirTra, Inc runs the higher net margin — -27.2% vs -507.8%, a 480.6% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -46.5%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -37.0%).
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
VirTra, Inc. is a global provider of highly realistic immersive training simulators and supporting curriculum, primarily serving law enforcement agencies, military units, and public safety organizations. Its scenario-based training systems are designed to enhance frontline personnel's decision-making, de-escalation skills, and on-duty operational safety.
TSHA vs VTSI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.5M | $2.9M |
| Net Profit | $-27.9M | $-792.4K |
| Gross Margin | — | 57.5% |
| Operating Margin | -516.0% | -47.9% |
| Net Margin | -507.8% | -27.2% |
| Revenue YoY | 171.3% | -46.5% |
| Net Profit YoY | -48.3% | 10.8% |
| EPS (diluted) | $-0.08 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $5.5M | $2.9M | ||
| Q3 25 | $0 | $5.3M | ||
| Q2 25 | $2.0M | $7.0M | ||
| Q1 25 | $2.3M | $7.2M | ||
| Q4 24 | $2.0M | $5.4M | ||
| Q3 24 | $1.8M | $7.5M | ||
| Q2 24 | $1.1M | $6.1M | ||
| Q1 24 | $3.4M | $7.3M |
| Q4 25 | $-27.9M | $-792.4K | ||
| Q3 25 | $-32.7M | $-388.6K | ||
| Q2 25 | $-26.9M | $175.3K | ||
| Q1 25 | $-21.5M | $1.3M | ||
| Q4 24 | $-18.8M | $-888.3K | ||
| Q3 24 | $-25.5M | $583.1K | ||
| Q2 24 | $-20.9M | $1.2M | ||
| Q1 24 | $-24.1M | $468.2K |
| Q4 25 | — | 57.5% | ||
| Q3 25 | — | 65.8% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 72.6% | ||
| Q4 24 | — | 67.5% | ||
| Q3 24 | — | 73.5% | ||
| Q2 24 | — | 90.9% | ||
| Q1 24 | — | 64.2% |
| Q4 25 | -516.0% | -47.9% | ||
| Q3 25 | — | -8.4% | ||
| Q2 25 | -1347.1% | 13.1% | ||
| Q1 25 | -930.5% | 19.1% | ||
| Q4 24 | -985.8% | -9.9% | ||
| Q3 24 | -1448.4% | 10.1% | ||
| Q2 24 | -1915.4% | 18.6% | ||
| Q1 24 | -713.3% | 8.9% |
| Q4 25 | -507.8% | -27.2% | ||
| Q3 25 | — | -7.3% | ||
| Q2 25 | -1353.6% | 2.5% | ||
| Q1 25 | -935.2% | 17.7% | ||
| Q4 24 | -929.0% | -16.3% | ||
| Q3 24 | -1427.5% | 7.8% | ||
| Q2 24 | -1882.0% | 19.8% | ||
| Q1 24 | -705.4% | 6.4% |
| Q4 25 | $-0.08 | $-0.08 | ||
| Q3 25 | $-0.09 | $-0.03 | ||
| Q2 25 | $-0.09 | $0.02 | ||
| Q1 25 | $-0.08 | $0.11 | ||
| Q4 24 | $-0.07 | $-0.08 | ||
| Q3 24 | $-0.10 | $0.05 | ||
| Q2 24 | $-0.09 | $0.11 | ||
| Q1 24 | $-0.10 | $0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $319.8M | $18.6M |
| Total DebtLower is stronger | — | $7.5M |
| Stockholders' EquityBook value | $246.9M | $45.6M |
| Total Assets | $343.3M | $65.1M |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $319.8M | $18.6M | ||
| Q3 25 | $297.3M | $20.8M | ||
| Q2 25 | $312.8M | $20.7M | ||
| Q1 25 | $116.6M | $17.6M | ||
| Q4 24 | $139.0M | $18.0M | ||
| Q3 24 | $157.7M | $19.7M | ||
| Q2 24 | $172.7M | $18.4M | ||
| Q1 24 | $124.0M | $22.4M |
| Q4 25 | — | $7.5M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $246.9M | $45.6M | ||
| Q3 25 | $219.0M | $46.3M | ||
| Q2 25 | $248.7M | $46.8M | ||
| Q1 25 | $55.1M | $46.5M | ||
| Q4 24 | $71.5M | $45.2M | ||
| Q3 24 | $88.8M | $45.7M | ||
| Q2 24 | $108.9M | $44.9M | ||
| Q1 24 | $53.8M | $43.5M |
| Q4 25 | $343.3M | $65.1M | ||
| Q3 25 | $316.6M | $66.2M | ||
| Q2 25 | $333.3M | $67.4M | ||
| Q1 25 | $138.4M | $66.8M | ||
| Q4 24 | $160.4M | $65.0M | ||
| Q3 24 | $180.2M | $66.1M | ||
| Q2 24 | $200.4M | $66.0M | ||
| Q1 24 | $153.0M | $69.4M |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.17× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.7M | $-1.5M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -72.5% |
| Capex IntensityCapex / Revenue | — | 21.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.7M | $-1.5M | ||
| Q3 25 | $-24.2M | $36.3K | ||
| Q2 25 | $-20.2M | $6.0M | ||
| Q1 25 | $-22.0M | $65.7K | ||
| Q4 24 | $-18.3M | $-908.7K | ||
| Q3 24 | $-21.6M | $897.7K | ||
| Q2 24 | $-21.5M | $-3.9M | ||
| Q1 24 | $-19.8M | $5.1M |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | $-24.3M | $-61.2K | ||
| Q2 25 | — | $5.4M | ||
| Q1 25 | — | $-362.7K | ||
| Q4 24 | $-18.3M | $-1.1M | ||
| Q3 24 | $-21.6M | $814.2K | ||
| Q2 24 | $-21.7M | $-3.9M | ||
| Q1 24 | $-19.9M | $3.6M |
| Q4 25 | — | -72.5% | ||
| Q3 25 | — | -1.1% | ||
| Q2 25 | — | 77.6% | ||
| Q1 25 | — | -5.1% | ||
| Q4 24 | -905.5% | -19.5% | ||
| Q3 24 | -1210.9% | 10.9% | ||
| Q2 24 | -1951.9% | -64.7% | ||
| Q1 24 | -584.5% | 48.9% |
| Q4 25 | — | 21.2% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 8.1% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | 0.1% | 2.8% | ||
| Q3 24 | 2.0% | 1.1% | ||
| Q2 24 | 18.1% | 1.0% | ||
| Q1 24 | 4.1% | 21.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 34.12× | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | -3.22× | ||
| Q1 24 | — | 10.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
